Anzeige
Erschienen in:
20.05.2020 | Original Article
A Phenome-Wide Analysis of Healthcare Costs Associated with Inflammatory Bowel Diseases
Erschienen in: Digestive Diseases and Sciences | Ausgabe 3/2021
Einloggen, um Zugang zu erhaltenAbstract
Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are associated with considerable direct healthcare costs. There have been few comprehensive analyses of all IBD- and non-IBD comorbidities that determine direct costs in this population.
Methods
We used data from a validated cohort of patients with inflammatory bowel disease (IBD). Total healthcare costs were estimated as a sum of costs associated with IBD-related hospitalizations and surgery, imaging (CT or MR scans), outpatient visits, endoscopic evaluation, and emergency room (ER) care. All ICD-9 codes were extracted for each patient and clustered into 1804 distinct phecode clusters representing individual phenotypes. A phenome-wide association analysis (PheWAS) was performed using logistic regression to identify predictors of being in the top decile of costs.
Results
Our cohort is comprised of 10,721 patients with IBD among whom 50% had CD. The median age was 46 years. The median total cost per patient is $11,203 (IQR $2396–30,563). The strongest association with total healthcare costs was intestinal obstruction without mention of hernia (p = 5.93 × 10−156) and other intestinal obstruction (p = 9.24 × 10−131). In addition, strong associations were observed for symptoms consistent with severity of IBD including the presence of fluid–electrolyte imbalance (p = 1.90 × 10−130), hypovolemia (p = 1.65 × 10−114), abdominal pain (p = 7.29 × 10−60), and anemia (p = 1.90–10−83). Cardiopulmonary diseases and psychological comorbidity also demonstrated significant associations with total costs with the latter being more strongly associated with ER visit-related costs.
Conclusions
Surrogate markers suggesting possible irreversible bowel damage and active disease demonstrate the greatest influence on IBD-related healthcare costs.